{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:39:22Z","timestamp":1789007962936,"version":"build-2803163510"},"reference-count":94,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.mcna.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T12:22:08Z","timestamp":1622204528000},"page":"757-782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Recognition and Management of Cutaneous Connective Tissue Diseases"],"prefix":"10.1016","volume":"105","author":[{"given":"Kylee J.B.","family":"Kus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery H.","family":"LaChance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Vleugels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mcna.2021.04.011_bib1","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1164\/rccm.201509-1881ED","article-title":"Screening and early detection of pulmonary arterial hypertension in connective tissue diseases: it is time to institute it!","volume":"192","author":"Khanna","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.011_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.berh.2013.07.008","article-title":"Cutaneous lupus erythematosus: diagnosis and treatment","volume":"27","author":"Okon","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.011_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archdermatol.2009.21","article-title":"Incidence of cutaneous lupus erythematosus, 1965-2005 a population-based study","volume":"145","author":"Durosaro","year":"2009","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.011_bib4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1365-2133.2011.10272.x","article-title":"Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden","volume":"164","author":"Gr\u00f6nhagen","year":"2011","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.mcna.2021.04.011_bib5","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology (United Kingdom)"},{"issue":"10","key":"10.1016\/j.mcna.2021.04.011_bib6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1177\/0961203310373780","article-title":"Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan","volume":"19","author":"Chiu","year":"2010","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/2229-5178.126020","article-title":"Cutaneous lupus erythematosus: an update","volume":"5","author":"Gr\u00f6nhagen","year":"2014","journal-title":"Indian Dermatol Online J"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1440-0960.2000.00443.x","article-title":"Epidemiology of cutaneous lupus erythematosus in a tertiary referral centre in Singapore","volume":"41","author":"Ng","year":"2000","journal-title":"Australas J Dermatol"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.011_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00128071-200304070-00002","article-title":"Cutaneous lupus erythematosus: diagnosis and management","volume":"4","author":"Fabbri","year":"2003","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2340\/0001555577305308","article-title":"Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients","volume":"77","author":"Tebbe","year":"1997","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"10.1016\/j.mcna.2021.04.011_bib11","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/0961203310370048","article-title":"Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates","volume":"19","author":"Obermoser","year":"2010","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.011_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11310780-000000000-00000","article-title":"Cutaneous lupus erythematosus: issues in diagnosis and treatment","volume":"10","author":"Walling","year":"2009","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.011_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clindermatol.2006.07.014","article-title":"Lupus erythematosus: systemic and cutaneous manifestations","volume":"24","author":"Rothfield","year":"2006","journal-title":"Clin Dermatol"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2021.04.011_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12016-007-0031-x","article-title":"Pathophysiology of cutaneous lupus erythematosus","volume":"33","author":"Lin","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1365-4362.2001.01067-5.x","article-title":"Subacute cutaneous lupus erythematosus with pityriasis-like cutaneous manifestations","volume":"40","author":"Caproni","year":"2001","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.mcna.2021.04.011_bib16","first-page":"1124","article-title":"Clinical manifestations of cutaneous lupus erythematosus","volume":"5","author":"Kuhn","year":"2007","journal-title":"J\u00a0Ger Soc Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.011_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2133.2012.10969.x","article-title":"Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden","volume":"167","author":"Gr\u00f6nhagen","year":"2012","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.mcna.2021.04.011_bib18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/0961203310370349","article-title":"Drug-induced subacute cutaneous lupus erythematosus","volume":"19","author":"Callen","year":"2010","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2133.2011.10610.x","article-title":"Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus","volume":"166","author":"Chong","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0560.2001.280101.x","article-title":"The cutaneous pathology of lupus erythematosus: a review","volume":"28","author":"Crowson","year":"2001","journal-title":"J\u00a0Cutan Pathol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.011_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/096120300678828569","article-title":"The spectrum of cutaneous manifestations in lupus erythematosus: the Italian experience","volume":"9","author":"Cardinali","year":"2000","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.011_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/08916930600886851","article-title":"Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies","volume":"39","author":"Lee","year":"2006","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2133.2009.09472.x","article-title":"Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients","volume":"162","author":"Vera-Recabarren","year":"2010","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.011_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00000372-199710000-00003","article-title":"Atypical lymphoid infiltrates arising in cutaneous lesions of connective tissue disease","volume":"19","author":"Magro","year":"1997","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.011_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/annrheumdis-2019-216155","article-title":"In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR\/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment","volume":"79","author":"Adamichou","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.011_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1191\/096120301675962535","article-title":"Skin lesions: an indicator of disease activity in systemic lupus erythematosus?","volume":"10","author":"Ze\u010devi\u0107","year":"2001","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.011_bib27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.autrev.2005.01.003","article-title":"Clinical manifestations of cutaneous lupus erythematosus","volume":"4","author":"Werth","year":"2005","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.mcna.2021.04.011_bib28","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/0961203310367656","article-title":"Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus","volume":"19","author":"Gr\u00f6nhagen","year":"2010","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.011_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/RHU.0b013e3181bb971b","article-title":"Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases","volume":"15","author":"Marin","year":"2009","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002954.pub2","article-title":"Drugs for discoid lupus erythematosus","author":"Jessop","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.mcna.2021.04.011_bib31","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/1756-185X.13676","article-title":"Association between circulating 25-hydroxyvitamin D and systemic lupus erythematosus: a systematic review and meta-analysis","volume":"22","author":"Guan","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"11","key":"10.1016\/j.mcna.2021.04.011_bib32","doi-asserted-by":"crossref","first-page":"102393","DOI":"10.1016\/j.autrev.2019.102393","article-title":"Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"18","author":"Parisis","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.011_bib33","doi-asserted-by":"crossref","first-page":"e0193728","DOI":"10.1371\/journal.pone.0193728","article-title":"Physical activity and sedentary behavior in patients with systemic lupus erythematosus","volume":"13","author":"Margiotta","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.clindermatol.2018.04.003","article-title":"Dermatomyositis: current concepts","volume":"36","author":"Bogdanov","year":"2018","journal-title":"Clin Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.011_bib35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.011_bib36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12016-017-8652-1","article-title":"Cutaneous manifestations of dermatomyositis: a comprehensive review","volume":"53","author":"Mainetti","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.011_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-020-00502-6","article-title":"Dermatomyositis: an update on diagnosis and treatment","volume":"21","author":"Cobos","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"10.1016\/j.mcna.2021.04.011_bib38","first-page":"722","article-title":"Prognostic factors and predictive signs of malignancy in adult dermatomyositis","volume":"123","author":"Gallais","year":"1996","journal-title":"Ann Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.011_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11926-011-0176-8","article-title":"Antisynthetase syndrome","volume":"13","author":"Katzap","year":"2011","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2020.02.061","article-title":"Malignancy in dermatomyositis: a retrospective study of 201 patients seen at the University of Pennsylvania","volume":"83","author":"Bowerman","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.011_bib41","doi-asserted-by":"crossref","first-page":"e9639","DOI":"10.1097\/MD.0000000000009639","article-title":"Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts","volume":"97","author":"Leatham","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.011_bib42","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/bjd.15607","article-title":"The pathogenesis of dermatomyositis","volume":"179","author":"Thompson","year":"2018","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.mcna.2021.04.011_bib43","doi-asserted-by":"crossref","first-page":"1057.e13","DOI":"10.1016\/j.crad.2018.07.106","article-title":"T2 mapping in dermatomyositis\/polymyositis and correlation with clinical parameters","volume":"73","author":"Ran","year":"2018","journal-title":"Clin Radiol"},{"issue":"12","key":"10.1016\/j.mcna.2021.04.011_bib44","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.011_bib45","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.14759","article-title":"Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients","volume":"32","author":"Best","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.011_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies","volume":"20","author":"Wolstencroft","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.011_bib47","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1378\/chest.12-0741","article-title":"Diagnosis and treatment of connective tissue disease-associated interstitial lung disease","volume":"143","author":"Vij","year":"2013","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.011_bib48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaad.2019.05.105","article-title":"Dermatomyositis: diagnosis and treatment","volume":"82","author":"Waldman","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib50","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40257-013-0028-6","article-title":"Cutaneous dermatomyositis: an updated review of treatment options and internal associations","volume":"14","author":"Femia","year":"2013","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.011_bib51","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3899\/jrheum.131145","article-title":"Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis: a randomized controlled single-blinded study with a 2-year followup","volume":"41","author":"Alexanderson","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.mcna.2021.04.011_bib52","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/rheumatology\/ker292","article-title":"Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy: a systematic review","volume":"50","author":"Habers","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib53","first-page":"1","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Prim"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.011_bib54","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.011_bib55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/1346-8138.14153","article-title":"Systemic sclerosis","volume":"45","author":"Asano","year":"2018","journal-title":"J\u00a0Dermatol"},{"issue":"10103","key":"10.1016\/j.mcna.2021.04.011_bib56","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.mcna.2021.04.011_bib57","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"Van Den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.011_bib59","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semarthrit.2015.04.009","article-title":"Thinking outside the box: the associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect","volume":"45","author":"Srivastava","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.mcna.2021.04.011_bib60","first-page":"106","article-title":"UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis","volume":"34","author":"Lynch","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib61","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/art.39490","article-title":"Derivation and external validation of a prediction rule for five-year mortality in patients with early diffuse cutaneous systemic sclerosis","volume":"68","author":"Domsic","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.mcna.2021.04.011_bib62","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib63","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jbspin.2019.09.015","article-title":"Systemic sclerosis: recent insight in clinical management","volume":"87","author":"Zanatta","year":"2020","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.mcna.2021.04.011_bib64","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clim.2018.12.006","article-title":"Intravenous immunoglobulin (IVIG) in the vanguard therapy of systemic sclerosis","volume":"199","author":"Gomes","year":"2019","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.mcna.2021.04.011_bib65","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.mcna.2021.04.011_bib66","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2147\/DDDT.S99696","article-title":"Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis","volume":"10","author":"Sakkas","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.011_bib67","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0308022617698167","article-title":"Long-term improvement in activities of daily living in women with systemic sclerosis attending occupational therapy","volume":"80","author":"Zanatta","year":"2017","journal-title":"Br J Occup Ther"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib68","first-page":"159","article-title":"Efficacy of intensive hand physical therapy in patients with systemic sclerosis","volume":"106","author":"Horv\u00e1th","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.011_bib69","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/jamadermatol.2019.0585","article-title":"Hyaluronidase treatment of scleroderma-induced microstomia","volume":"155","author":"Melvin","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.mcna.2021.04.011_bib70","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.011_bib71","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib72","doi-asserted-by":"crossref","DOI":"10.1177\/2045893217748307","article-title":"The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study","volume":"8","author":"Sato","year":"2018","journal-title":"Pulm Circ"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib73","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","article-title":"Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature","volume":"16","author":"Sanges","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.011_bib74","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/MCG.0000000000000334","article-title":"Gastrointestinal manifestations, malnutrition, and role of enteral and parenteral nutrition in patients with scleroderma","volume":"49","author":"Bharadwaj","year":"2015","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10067-019-04564-8","article-title":"Use of vasoactive\/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study","volume":"39","author":"Blagojevic","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.011_bib76","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1610-0387.2007.06279.x","article-title":"Therapeutic options for digital ulcers in patients with systemic sclerosis","volume":"5","author":"Chung","year":"2007","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1346-8138.13030","article-title":"Beneficial effect of botulinum toxin A on Raynaud\u2019s phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study","volume":"43","author":"Motegi","year":"2016","journal-title":"J\u00a0Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.011_bib78","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/01.dad.0000181109.54532.c5","article-title":"Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis","volume":"27","author":"Carlson","year":"2005","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.1780390103","article-title":"Pathology and pathogenesis of vascular injury in systemic lupus erythematosus Interactions of inflammatory cells and activated endothelium","volume":"39","author":"Belmont","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.011_bib80","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00128071-200809020-00001","article-title":"Clinical approach to cutaneous vasculitis","volume":"9","author":"Chen","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1440-0960.2005.00127.x","article-title":"Golfer\u2019s vasculitis","volume":"46","author":"Kelly","year":"2005","journal-title":"Australas J Dermatol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib82","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1468-3083.2006.01504.x","article-title":"Exercise-induced vasculitis","volume":"20","author":"Ramelet","year":"2006","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.011_bib83","first-page":"403","article-title":"Cutaneous vasculitis in children and adults: associated diseases and etiologic factors in 303 patients","volume":"77","author":"Blanco","year":"1998","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.011_bib84","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/01.dad.0000246646.45651.a2","article-title":"Cutaneous vasculitis update: small vessel neutrophilic vasculitis syndromes","volume":"28","author":"Carlson","year":"2006","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.011_bib85","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1067\/mjd.2003.212","article-title":"Cutaneous vasculitis","volume":"48","author":"Fiorentino","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib86","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1345\/aph.1A124","article-title":"Cutaneous and systemic manifestations of drug-induced vasculitis","volume":"36","author":"Holder","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib87","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/01.dad.0000245198.80847.ff","article-title":"Cutaneous vasculitis update: neutrophilic muscular vessel and eosinophilic, granulomatous, and lymphocytic vasculitis syndromes","volume":"29","author":"Carlson","year":"2007","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib88","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.autrev.2012.08.005","article-title":"Skin involvement in cutaneous and systemic vasculitis","volume":"12","author":"Marzano","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib89","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/j.tvir.2014.11.005","article-title":"Polyarteritis nodosa","volume":"17","author":"Howard","year":"2014","journal-title":"Tech Vasc Interv Radiol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.011_bib90","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0560.2006.00614.x","article-title":"Granulomatous arteritis in cutaneous lesions of Churg-Strauss syndrome","volume":"34","author":"Chen","year":"2007","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.mcna.2021.04.011_bib91","first-page":"305","article-title":"Cutaneous vasculitis and cancer: a clinical approach","volume":"18","author":"Gonz\u00e1lez-Gay","year":"2000","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.011_bib92","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00002281-200101000-00005","article-title":"\u201cEssential\u201d cutaneous vasculitis: what every rheumatologist should know about vasculitis of the skin","volume":"13","author":"Stone","year":"2001","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.011_bib93","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0738-081X(99)00075-9","article-title":"Common mistakes in the clinical approach to vasculitis","volume":"17","author":"Ryan","year":"1999","journal-title":"Clin Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.011_bib94","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.clindermatol.2006.07.007","article-title":"Cutaneous vasculitis: diagnosis and management","volume":"24","author":"Carlson","year":"2006","journal-title":"Clin Dermatol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T23:24:23Z","timestamp":1710458663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712521000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0025712521000493"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2021.04.011","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recognition and Management of Cutaneous Connective Tissue Diseases","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}